Equillium Bio
  • Our Company
    • About Us
    • Executive Team
    • Board of Directors
    • Scientific and Clinical Advisors
    • Partners
  • Our Science
    • Overview
    • CD6-ALCAM Pathway
    • Itolizumab
    • Publications & Presentations
  • Pipeline
    • Overview
    • Pipeline Graphic
    • Clinical Trials
  • Patients
    • Overview
    • Therapeutic Areas
      • Graft-Versus-Host Disease
      • Uncontrolled Moderate to Severe Asthma
      • SLE / Lupus Nephritis
    • Clinical Trials
      • The EQUATE study
      • The EQUIP study
      • The EQUALISE Study
  • Investors
    • Investors Overview
    • Stock Quote & Chart
    • Historical Price Lookup
    • News
    • Events & Presentations
    • Analyst Coverage
    • SEC Fillings
    • Governance Highlights
    • Committee Composition
    • Investor FAQ
    • Alerts & Contacts
  • Careers
  • Contact Us
  • Menu

EQUATE, a Phase 1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of a novel targeted anti-CD6 therapy, itolizumab, in subjects with newly diagnosed acute graft versus host disease

John Koreth et. al., 2019

2021 © Equillium, Inc. EDPO Certification | Privacy Notice
Scroll to top